CN103041069A - Pure Chinese medicinal composition for hyperlipidemia obesity and preparation method thereof - Google Patents
Pure Chinese medicinal composition for hyperlipidemia obesity and preparation method thereof Download PDFInfo
- Publication number
- CN103041069A CN103041069A CN2011104088963A CN201110408896A CN103041069A CN 103041069 A CN103041069 A CN 103041069A CN 2011104088963 A CN2011104088963 A CN 2011104088963A CN 201110408896 A CN201110408896 A CN 201110408896A CN 103041069 A CN103041069 A CN 103041069A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- hyperlipidemia
- obesity
- pure chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 16
- 208000008589 Obesity Diseases 0.000 title claims abstract description 14
- 235000020824 obesity Nutrition 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000002775 capsule Substances 0.000 claims abstract description 11
- 235000016425 Arthrospira platensis Nutrition 0.000 claims abstract description 9
- 240000002900 Arthrospira platensis Species 0.000 claims abstract description 9
- 229940082787 spirulina Drugs 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 18
- 241000756943 Codonopsis Species 0.000 claims description 8
- 241000222640 Polyporus Species 0.000 claims description 8
- 241000207929 Scutellaria Species 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 3
- 239000012567 medical material Substances 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 7
- 210000000952 spleen Anatomy 0.000 abstract description 2
- 241000007126 Codonopsis pilosula Species 0.000 abstract 1
- 241000222684 Grifola Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 241000219784 Sophora Species 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 231100000957 no side effect Toxicity 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- 238000004163 cytometry Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a pure Chinese medicinal composition for hyperlipidemia obesity and a preparation method thereof. The composition comprises the following components in parts by weight: 100 parts of spirulina, 60 parts of baikal skullcap root, 120 parts of rhizoma alismatis, 60 parts of codonopsis pilosula, 60 parts of subprostrate sophora, 120 parts of grifola, 50 parts of folium sennae, and 50 parts of polygonum cuspidatum. The medicinal composition for hyperlipidemia obesity is a pure Chinese medicinal capsule, which can be used for soothing liver-qi stagnation, invigorating spleen and supplementing qi, removing stasis, reducing fat and losing weight and promoting fat metabolism by regulating body performance, so that the effect of treating hyperlipidemia and simple obesity can be achieved. The Chinese medicinal composition has the advantages of high safety, no toxic or side effect, no dependence, stable and controllable quality, simple preparation process and the like, is convenient for carrying and taking and can be produced by virtue of conventional equipment.
Description
Technical field
The invention belongs to medicine field, particularly relate to a kind of pure Chinese medicine combination for the hyperlipidemia obesity and preparation method thereof.。
Background technology
At present, now the product about blood fat reducing and fat-reducing is a lot of on the market, but have effective, long-term taking safely, have no side effect, the product of no dependence seldom.
Summary of the invention
Purpose of the present invention aims to provide a kind of pure Chinese medicine combination for the hyperlipidemia obesity and preparation method thereof, it can overcome the shortcoming of existing market existing procucts, and have effective, safe, have no side effect, no dependence, stable and controllable for quality, be easy to carry and take, the simple advantage of preparation technology.
Technical scheme of the present invention is: a kind of pure Chinese medicine combination for the hyperlipidemia obesity is provided, it is characterized in that crude drug composition and weight proportion thereof that it contains are: 100 parts of spirulinas, 60 parts of Radix Scutellariaes, 120 parts of Rhizoma Alismatis, 60 parts of Radix Codonopsis, 60 parts of Radix Sophorae Tonkinensiss, 120 parts of Polyporus, 50 parts of Folium Sennae, Rhizoma Polygoni Cuspidati 50g part.
Its preparation method of described a kind of pure Chinese medicine combination for the hyperlipidemia obesity is characterized in that it may further comprise the steps:
1) by following weight ratio weighting raw materials: 100 parts of spirulinas, 60 parts of Radix Scutellariaes, 120 parts of Rhizoma Alismatis, 60 parts of Radix Codonopsis, 60 parts of Radix Sophorae Tonkinensiss, 120 parts of Polyporus, 50 parts of Folium Sennae, Rhizoma Polygoni Cuspidati 50g part;
2) above-mentioned eight flavor medical materials are got Radix Scutellariae, Rhizoma Alismatis, Rhizoma Polygoni Cuspidati and are ground into respectively fine powder, cross 80 mesh sieves, and are for subsequent use;
3) Radix Codonopsis, Radix Sophorae Tonkinensis, Polyporus, Folium Sennae decoct with water twice, and 2 hours for the first time, 1 hour for the second time, merge and fry in shallow oil night, filter, filter is condensed into clear paste to the clear paste of relative density 1.15-1.25 night;
4) spirulina and (2) are added in (3) mix homogeneously, 50 ℃ of drying under reduced pressure;
5) (4) are pulverized, cross 40 mesh sieves; Upper capsule filling machine carries out filling, gets final product;
6) inner packing;
7) outer package, product inspection, warehouse-in.
The capsule of the pure Chinese medicine combination among the present invention reaches to realize dispersing the stagnated live-QI to relieve the stagnation of QI with the balance the body function, and turbid amassing dispelled in invigorating the spleen and benefiting QI, and lowering blood-fat and reducing weight promotes lipid metabolism, and then reaches the effect for the treatment of hyperlipidemia and simple obesity.
Advantage of the present invention is: Chinese medicine composition of the present invention have safe, have no side effect, no dependence, stable and controllable for quality, be easy to carry and take, the advantage such as preparation technology is simple.
The specific embodiment
The invention will be further described below in conjunction with specific embodiment, but not as limitation of the present invention.The part that is not described in detail in the present embodiment is to adopt prior art, and industry standard or known approaches.
Embodiment
Described pure Chinese medicine combination capsule adopts following steps to make:
1) takes by weighing raw material by following weight ratio: 100 parts of spirulinas, 60 parts of Radix Scutellariaes, 120 parts of Rhizoma Alismatis, 60 parts of Radix Codonopsis, 60 parts of Radix Sophorae Tonkinensiss, 120 parts of Polyporus, 50 parts of Folium Sennae, Rhizoma Polygoni Cuspidati 50g part;
2) above-mentioned eight flavor medical materials are got Radix Scutellariae, Rhizoma Alismatis, Rhizoma Polygoni Cuspidati and are ground into respectively fine powder, cross 80 mesh sieves, and are for subsequent use.
3) Radix Codonopsis, Radix Sophorae Tonkinensis, Polyporus, Folium Sennae decoct with water twice, and 2 hours for the first time, 1 hour for the second time, merge and fry in shallow oil night, filter, filter is condensed into clear paste to the clear paste of relative density (1.15-1.25) night;
4) spirulina and (2) are added in (3) mix homogeneously, 50 ℃ of drying under reduced pressure;
5) (4) are pulverized, cross 40 mesh sieves; Upper capsule filling machine carries out filling, gets final product;
6) inner packing;
7) outer package, product inspection, warehouse-in.
The below is the clinical observation of a kind of pure Chinese medicine combination capsule for treating hyperlipidemia for the hyperlipidemia obesity of the embodiment of the invention:
Case is selected
Except the age person below 40 years old, suffer from outside the Secondary Hyperlipidemia due to diabetes, hypothyroidism, nephrotic syndrome, the acute and chronic liver and gall diseases etc., all include the research case in.Totally 160 examples are divided into 2 groups at random, and treatment group is taken embodiment of the invention capsule 86 examples, male 52 examples, women 34 examples, 61.50 years old mean age; Matched group 74 examples, male 45 examples, women 29 examples, 62.80 years old mean age.Two groups of ages and the equal no significant difference of severity extent.
Therapeutic Method
All cases is measured TC, TG, HDL-C, LDL-C on an empty stomach before administration.The pure Chinese medicine combination capsule that is used for the hyperlipidemia obesity described in the oral inventive embodiments for the treatment of group, 0.9g/ grain, twice of every day, the oral simvastatin sheet of matched group 20mg (20mg/ sheet), night every day decoction being taken at a draught, all took continuously for 6 weeks for 2 groups, at inactive other fat-reducing medicament of viewing duration, measure on an empty stomach weekly TC, TG, HDL-C, LDL-C after taking medicine.Should make regular check on blood fat, hepatic and renal function, cytometry, blood creatine phosphokinase during the treatment.
The result
By as seen from Table 2,2 groups of forward and backward serum TC, TG, LDL-C of patient treatment all have obvious decline.Treatment group and the matched group HDL-C level that all can obviously raise and is compared P＜0.05 before the treatment.The effect for reducing blood fat that shows 2 groups is suitable.But the horizontal effect of Chinese medicinal capsule rising HDL-C involved in the present invention is better than matched group.
Untoward reaction
2 groups of hepatic and renal functions, cytometry Non Apparent Abnormalities change, and treatment group has 4 routine blood creatine phosphokinases to raise, but without clinical symptoms.
This research by with the contrast of Simvastatin Treatment hyperlipemia curative effect, prove that Chinese medicinal capsule involved in the present invention reduces cholesterolemia and triglyceride, increases the blood high density lipoprotein level obvious from curative effect.During clinical observation, have no serious adverse reaction.Therefore think Chinese medicine combination of the present invention have safe, have no side effect, no dependence, stable and controllable for quality, be easy to carry and take, the advantage such as preparation technology is simple, conventional equipment can be finished production, is worth further research.
Claims (2)
1. a pure Chinese medicine combination that is used for the hyperlipidemia obesity is characterized in that crude drug composition and weight proportion thereof that it contains are: 100 parts of spirulinas, 60 parts of Radix Scutellariaes, 120 parts of Rhizoma Alismatis, 60 parts of Radix Codonopsis, 60 parts of Radix Sophorae Tonkinensiss, 120 parts of Polyporus, 50 parts of Folium Sennae, Rhizoma Polygoni Cuspidati 50g part.
2. its preparation method of described a kind of pure Chinese medicine combination for the hyperlipidemia obesity is characterized in that it may further comprise the steps:
1) by following weight ratio weighting raw materials: 100 parts of spirulinas, 60 parts of Radix Scutellariaes, 120 parts of Rhizoma Alismatis, 60 parts of Radix Codonopsis, 60 parts of Radix Sophorae Tonkinensiss, 120 parts of Polyporus, 50 parts of Folium Sennae, Rhizoma Polygoni Cuspidati 50g part;
2) above-mentioned eight flavor medical materials are got Radix Scutellariae, Rhizoma Alismatis, Rhizoma Polygoni Cuspidati and are ground into respectively fine powder, cross 80 mesh sieves, and are for subsequent use;
3) Radix Codonopsis, Radix Sophorae Tonkinensis, Polyporus, Folium Sennae decoct with water twice, and 2 hours for the first time, 1 hour for the second time, merge and fry in shallow oil night, filter, filter is condensed into clear paste to the clear paste of relative density 1.15-1.25 night;
4) spirulina and (2) are added in (3) mix homogeneously, 50 ℃ of drying under reduced pressure;
5) (4) are pulverized, cross 40 mesh sieves; Upper capsule filling machine carries out filling, gets final product;
6) inner packing;
7) outer package, product inspection, warehouse-in.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110408896.3A CN103041069B (en) | 2011-12-11 | 2011-12-11 | Pure Chinese medicinal composition for hyperlipidemia obesity and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110408896.3A CN103041069B (en) | 2011-12-11 | 2011-12-11 | Pure Chinese medicinal composition for hyperlipidemia obesity and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103041069A true CN103041069A (en) | 2013-04-17 |
| CN103041069B CN103041069B (en) | 2014-12-17 |
Family
ID=48054080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110408896.3A Active CN103041069B (en) | 2011-12-11 | 2011-12-11 | Pure Chinese medicinal composition for hyperlipidemia obesity and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103041069B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103446571A (en) * | 2013-09-22 | 2013-12-18 | 曹丽荣 | Drug for dispelling dampness and losing weight |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105288498A (en) * | 2015-12-02 | 2016-02-03 | 青岛华之草医药科技有限公司 | Method for preparing folium artemisiae argyi-contained traditional Chinese medicine preparation capable of treating obesity |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101757598A (en) * | 2009-11-05 | 2010-06-30 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine composition for treating advanced malignant liver tumor symptoms and preparation method thereof |
-
2011
- 2011-12-11 CN CN201110408896.3A patent/CN103041069B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101757598A (en) * | 2009-11-05 | 2010-06-30 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine composition for treating advanced malignant liver tumor symptoms and preparation method thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103446571A (en) * | 2013-09-22 | 2013-12-18 | 曹丽荣 | Drug for dispelling dampness and losing weight |
| CN103446571B (en) * | 2013-09-22 | 2015-06-03 | 曹丽荣 | Drug for dispelling dampness and losing weight |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103041069B (en) | 2014-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190038699A1 (en) | Seven-star tea without excipient and method of preparing the same | |
| CN105105116A (en) | Health food with effects of relieving physical fatigue and enhancing immunity and preparation method of health food | |
| CN103341052A (en) | Medicine for preventing and treating hypertension, hyperlipidemia, hyperglycemia and hypotension and preparation method thereof | |
| CN1054370A (en) | A kind of manufacture method of kidney-tonifying health-care medicament | |
| CN103041069B (en) | Pure Chinese medicinal composition for hyperlipidemia obesity and preparation method thereof | |
| CN104288344B (en) | Application of Pu' er tea extract in preparation of medicine or food for regulating intestinal flora and relaxing bowels | |
| CN100345566C (en) | Medicine composition used for reducing weight, prepn. method and use thereof | |
| CN101524441A (en) | Chinese medicinal composition for lipid-lowering and weight-losing and preparation method thereof | |
| CN102640921A (en) | Dietary anti-aging tea granules | |
| CN102640825B (en) | Lipid-lowering tea for regulating blood lipid | |
| CN101940696A (en) | Method for preparing Chinese medicinal compound Zengshengping | |
| CN108077702A (en) | Pueraria lobata radix polygonati officinalis solid beverage and preparation method | |
| CN106309729B (en) | A kind of Chinese medicine composition adjusting chronic hepatitis immune function | |
| CN107281386B (en) | Method for preparing medicine for treating hypertension by using dendrobium officinale and radish seeds and application | |
| CN104069144A (en) | Three formula granules for forming Shengmai powder and preparation method thereof | |
| CN108404088B (en) | Traditional Chinese medicine for treating type II diabetes and preparation method thereof | |
| CN103285277A (en) | Umbilical sticking agent for reducing weight and preparation method thereof | |
| CN102669344A (en) | Food senescence delaying tea granule | |
| CN107582866B (en) | Application method of dendrobium officinale and amlodipine in preparation of medicine for treating hypertension | |
| CN104707106A (en) | Traditional Chinese medicine composition for treating fatty liver and preparation method thereof | |
| CN105125639A (en) | Traditional Chinese medicine composition for preventing and treating mastitis of dairy cattle | |
| CN103356924A (en) | Drug for preventing and treating fatty liver and preparation method thereof | |
| CN102614271A (en) | Chinese medicine for treating diabetic dyslipidemia | |
| CN102078562B (en) | Chinese medicinal oral liquid for treating children metabolic syndrome and preparation method thereof | |
| CN102366537A (en) | Traditional Chinese medicine preparation for treating cough caused by lung dryness and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information |
Inventor after: Tang Yonghong Inventor after: Song Zhe Inventor after: Song Yuanzhi Inventor before: Song Yuanzhi Inventor before: Song Zhe Inventor before: Tang Yonghong |
|
| CB03 | Change of inventor or designer information | ||
| CP03 | Change of name, title or address |
Address after: Room 1, No. 710077 B601 gazelle Valley in Shaanxi province high tech Zone of Xi'an Jinye Road No. 69 business development park C District Patentee after: XI'AN TAIKOMED MEDICAL TECHNOLOGY Co.,Ltd. Address before: 710077, 1-10502B, No. 2, No. 85, No. 3 Road, Xi'an hi tech Zone, Shaanxi Patentee before: Xi'an Takomed Pharmaceutical Technology Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240613 Address after: Room 1311, Building C, Chengfang Creation Century Plaza, No. 120 Yongwan Road, Xiuying District, Haikou City, Hainan Province, 570100 Patentee after: Jiayuan Pharmaceutical Investment (Hainan) Co.,Ltd. Country or region after: China Patentee after: Suzhou Guochen Enterprise Management Partnership (Limited Partnership) Address before: Room B601, gazelle Valley, No.1, Zone C, venture R & D Park, 69 Jinye Road, high tech Zone, Xi'an City, Shaanxi Province, 710077 Patentee before: XI'AN TAIKOMED MEDICAL TECHNOLOGY Co.,Ltd. Country or region before: China |
|
| TR01 | Transfer of patent right |